The ERC-PoC grant allowed us to achieve significant milestones in developing an innovative allergen immunotherapy using consensus allergens and mRNA technology. We successfully immunized naïve mice with consensus allergens in both mRNA and protein formats, resulting in the production of antibodies with broad binding capacity to a panel of recombinant allergens, demonstrating extensive therapeutic potential. These antibodies were able to block the binding of IgEs from patients, highlighting their potential for blocking therapy
Add to favorites:
Share:
My note
Please log in and activate Personal or Professional to use private notes for this listing.
Listing Description
Addressing target audiences and expressing needs
- Grants and Subsidies
- Collaboration
- Fellowship to advance my/our research
We are publishing here the scientific results of our ERC-PoC grant AIDA (ERC-2022-POC2-101112851). A complete set of the results can be consulted here: https://www.biorxiv.org/content/10.1101/2024.02.26.582073v1
- Public or private funding institutions
- Research and Technology Organisations
- Academia/ Universities
R&D, Technology and Innovation aspects
The innovative aspect of our proposal focuses on completing the data package by optimizing the lipid nanoparticle (LNP) composition, which is crucial for the effective delivery of our mRNA-based therapy. The optimization of LNPs aims to enhance the stability and delivery efficiency of the mRNA, ensuring a robust and sustained therapeutic effect. Additionally, we aim to obtain proof of concept in an allergic mouse model, demonstrating that our optimized LNP-mRNA formulation can protect against anaphylactic shock upon exposure to allergens. Transitioning from bench to bedside requires both scientific and technical advancements as well as a strategic approach to clinical trials and commercialization. Therefore, we are focusing on establishing a comprehensive company strategy and a viable investment plan. This includes defining and establishing upstream partnership strategies, initiating business development activities to support the long-term strategy, ensuring clinical and commercial manufacturing readiness, and closely monitoring our freedom to operate within the patent landscape.
The results havve been repeated at least three times in duplicates anb the statistical significance is stated in the linked pre-print
- Europe
- North America
- Global
Offer Details
Specifications and Deliverables:
Value Proposition:
We aim to treat allergy to multiple sources with a single treatment, faster, and more effectively than the current immunotherapy by combining two key concepts: consensus allergens and mRNA technology.
Input Required from Customer:
Fields of Application:
Patent/Publication Number
Main Patent Claims:
Patent Family:
Video
Documents
No documents available.
Location and Map
Sorry, no records were found. Please adjust your search criteria and try again.
Sorry, unable to load the Maps API.
Adress:
Brussels
Brussels
1040
Belgium
Contact the listings owner
Connect with the Listing Owner!
💬 Please log in now to send a direct message to the listing owner. Not a member yet? Sign up for free and start connecting today!
Related Funding and Finance Opportunities
Unlock Exclusive Funding Opportunities!
🔑 Get instant access to tailored funding opportunities that perfectly match your needs. This powerful feature is exclusively available to our professional members—helping you save time, stay ahead of the competition, and secure the right funding faster.
Upgrade to Professional now and never miss an important opportunity again! Already a member? Log in here to explore your matches.
Related Offers
Unlock Related Offers!
🚀 Gain access to related technology solutions that match your specific needs and interests—carefully selected to support your innovation goals. These offers are exclusively available to our professional members, helping you identify relevant technologies faster and start the right conversations with potential partners.
Upgrade to Professional now and never miss an important opportunity again! Already a member? Log in here to explore your matches.
Related Knowledgeable Resources
Discover More with Professional: Related Knowledge Resources
🔒 You’re missing out on expert-curated knowledge specifically matched to this topic. As a professional member, you gain exclusive access to in-depth articles, guides, and insights that help you make smarter decisions, faster.
Whether you’re preparing a funding proposal, researching a new market, or just need reliable information—our professional knowledge matches save you hours of research and point you directly to what matters.
Upgrade to Professional now and instantly unlock relevant knowledge tailored to your needs! Already a member? Log in here to view your personalized content.
Viewers
See Who’s Interested in Your Offers!
🎯 Curious about who’s viewing your listings? Unlock insights into your last 20 visitors and discover potential leads instantly! This exclusive feature is only available to our professional members—helping you track engagement, connect with the right audience, and maximize your opportunities.
Upgrade to Professional now to gain access! Already a member? Log in here.

